Growth Hormone Stimulation Test: What Your Number Changes About Your Treatment

What a GH Stimulation Test Actually Measures

Your pituitary gland stores growth hormone and releases it in pulses, mostly during sleep and exercise. A single random blood draw cannot diagnose deficiency because GH levels fluctuate from undetectable to double digits within hours. The stimulation test solves this problem by forcing the pituitary to release its stored GH using a pharmacologic trigger, then measuring the peak response.

The concept is straightforward: give the body a signal that should cause a GH surge, draw blood at timed intervals (typically 0, 30, 60, 90, and 120 minutes), and see how high GH climbs. If the peak stays flat, the pituitary is failing. The 2011 Endocrine Society Clinical Practice Guideline states that "GH stimulation testing is required to diagnose adult GH deficiency" in patients without a known hypothalamic-pituitary structural cause and fewer than three other pituitary hormone deficits [1]. Patients with three or more pituitary deficits plus a low IGF-1 have a greater than 95% probability of GH deficiency and may not require provocative testing at all [1].

Random GH levels are clinically useless for diagnosis. A level of 0.1 ng/mL at 2 PM in a healthy adult means nothing. The stimulated peak is what matters. BMI also affects interpretation. Adiposity suppresses GH secretion even in people with normal pituitary function, so test-specific and BMI-specific cutoffs exist to prevent false-positive diagnoses [2].

The Tests and Their Cutoffs

Three validated provocative tests dominate current practice, and each carries its own diagnostic threshold. Choosing the wrong cutoff for the wrong test leads to misdiagnosis in both directions.

Insulin Tolerance Test (ITT). The ITT remains the reference standard endorsed by the Endocrine Society and AACE [1][3]. Insulin (0.1 to 0.15 U/kg IV) induces hypoglycemia (blood glucose <40 mg/dL), which triggers a counter-regulatory GH surge. A peak GH <3 ng/mL confirms severe GH deficiency in adults. The ITT requires medical supervision because of seizure and cardiovascular risk. It is contraindicated in patients with coronary artery disease, seizure disorders, or age over 65 [1].

Glucagon Stimulation Test (GST). For patients who cannot safely undergo insulin-induced hypoglycemia, the GST is the most widely used alternative. Glucagon (1 mg IM, or 1.5 mg if body weight exceeds 90 kg) stimulates GH release over 3 to 4 hours. The 2019 AACE guidelines recommend a peak cutoff of <3 ng/mL for non-obese adults [3]. A study by Yuen et al. (2009, N=168) demonstrated that in obese individuals (BMI ≥30), a lower cutoff of <1 ng/mL improved specificity from 68% to 97% [2]. Ignoring BMI adjustments means labeling healthy obese patients as GH-deficient.

Macimorelin Oral Test. The FDA approved macimorelin (Macrilen) in December 2017 as the first oral GH stimulation test [4]. Patients drink a single dose (0.5 mg/kg), and blood is drawn at 30, 45, 60, and 90 minutes. Peak GH <2.8 ng/mL confirms deficiency. The registration trial by Garcia et al. (J Clin Endocrinol Metab, 2018, N=157) showed 87% sensitivity and 96% specificity versus the ITT as reference, with a negative predictive value of 96% [5]. The test takes 90 minutes, does not require IV access, and carries no hypoglycemia risk.

How Your Peak Number Shapes the Diagnosis

The distance between your peak GH and the cutoff matters clinically. It is not a binary pass/fail situation in every case.

A peak of 0.2 ng/mL on an ITT signals near-total pituitary failure. A peak of 2.5 ng/mL sits just below the 3 ng/mL cutoff and warrants confirmatory testing with a second stimulation agent, especially if the clinical picture is ambiguous [1]. The Endocrine Society recommends two failed tests in patients with isolated suspected GH deficiency and no structural pituitary disease [1].

For patients in the "gray zone" (peak GH between 3 and 5 ng/mL), clinicians weigh additional factors: IGF-1 level relative to age-adjusted reference range, number of other pituitary deficits, MRI findings, history of cranial irradiation, and symptom burden measured by the QoL-AGHDA questionnaire. A peak of 4.2 ng/mL with a low IGF-1, prior pituitary surgery, and two other hormone deficits is treated very differently from the same number in an otherwise healthy 55-year-old with obesity.

Age influences both the response and the interpretation. The KIMS database (Pfizer International Metabolic Database, N=1,034) showed that GH-deficient adults diagnosed after age 60 had peak stimulated GH values that were significantly lower than those diagnosed between ages 25 and 40 (mean 0.7 vs. 1.4 ng/mL, P<0.01), and they also showed smaller treatment responses [6]. Starting doses must account for this.

What Happens After a Confirmed Low Result

Once a stimulation test confirms GH deficiency, your endocrinologist will initiate recombinant human GH (rhGH) at a weight-independent starting dose. Older weight-based protocols (0.006 mg/kg/day) produced more side effects, particularly in women and older patients [7].

The 2011 Endocrine Society guideline recommends starting at 0.1 to 0.2 mg/day for patients under 30 without obesity, 0.1 to 0.15 mg/day for those 30 to 60, and 0.1 mg/day for patients over 60 [1]. Women on oral estrogen require higher doses (often 0.2 to 0.3 mg/day) because first-pass hepatic estrogen metabolism suppresses IGF-1 generation [1]. Dr. Beverly Biller of Massachusetts General Hospital has noted that "women on oral estrogen replacement require approximately twice the GH dose of men to achieve the same IGF-1 response" [7].

Dose titration follows IGF-1 levels, not GH levels. The target is an IGF-1 in the upper half of the age-adjusted normal range. Blood draws occur every 4 to 6 weeks during titration. Once stable, monitoring moves to every 6 months for the first year, then annually [1]. The GH stimulation test itself is generally not repeated after treatment begins. Treatment adequacy is tracked through IGF-1, clinical response, and metabolic markers.

When a High or "Normal" Result Changes Your Plan

A peak GH above 5 ng/mL on a properly conducted ITT effectively rules out severe adult GH deficiency. Treatment with rhGH is not indicated, and prescribing it carries risk without proven benefit.

Some patients with suggestive symptoms (fatigue, increased body fat, decreased muscle mass) will test normal. In these cases, the GH axis is functioning, and the symptoms have a different cause. The AACE 2019 guidelines state that "GH therapy should not be prescribed to adults who have not been diagnosed with GH deficiency by means of a provocative test" [3].

A genuinely elevated peak (above 40 to 50 ng/mL at baseline, not just after stimulation) raises concern for acromegaly. That is a different diagnostic pathway involving oral glucose suppression testing and MRI. Random GH levels above 1 ng/mL that fail to suppress below 0.4 ng/mL after 75 g oral glucose are the standard diagnostic criteria for acromegaly per the 2014 Endocrine Society guideline [8].

IGF-1: The Partner Lab That Completes the Picture

The GH stimulation test and serum IGF-1 work as a diagnostic pair. IGF-1 is produced in the liver in response to GH signaling and has a long half-life (18 to 20 hours), making it a stable marker of overall GH activity.

A low IGF-1 (below the age-adjusted reference range) combined with a failed stimulation test makes the diagnosis virtually certain. A low IGF-1 alone is not diagnostic because malnutrition, liver disease, poorly controlled diabetes, and hypothyroidism all suppress IGF-1 independently of the GH axis [1]. The Endocrine Society guideline specifies that "a normal IGF-1 level does not exclude GH deficiency" [1].

During treatment, IGF-1 is the primary dose-adjustment biomarker. Exceeding the upper limit of the age-adjusted range for prolonged periods increases the theoretical risk of adverse outcomes. The Dutch National Registry of GH Treatment in Adults (N=2,229) found that patients maintained in the upper quartile of IGF-1 SDS had higher rates of fluid retention and arthralgia compared to those in the mid-normal range (18.3% vs. 9.7%, P<0.001) [9]. The recommendation: aim for mid-normal IGF-1, not maximum normal.

Factors That Can Blunt Your Test and Cause a False Low

Several conditions reduce stimulated GH peaks even when pituitary function is intact. Recognizing these prevents unnecessary treatment.

Obesity is the most common confounder. Visceral adiposity suppresses GH secretion through elevated free fatty acids, hyperinsulinemia, and increased somatostatin tone [2]. A BMI of 35 can cut the stimulated GH peak by 50% or more compared to a lean individual. This is why the GST uses BMI-stratified cutoffs.

Medications also interfere. Glucocorticoids suppress the GH axis dose-dependently. Opioids blunt GH responses. Atypical antipsychotics (particularly olanzapine and risperidone) can suppress GH through dopamine blockade [10]. The clinician should review the medication list before testing and, when possible, hold interfering drugs for an appropriate washout period.

Age itself reduces GH output. After age 30, basal GH secretion declines approximately 14% per decade [6]. By age 60, stimulated peaks in healthy adults are roughly half those seen at age 25. This normal decline does not constitute pathologic GH deficiency, and test interpretation must account for age-appropriate norms.

Poorly controlled hypothyroidism suppresses GH responses and must be corrected before testing. Similarly, untreated cortisol deficiency can blunt the response, so patients with suspected multiple pituitary hormone deficits should have thyroid and adrenal axes replaced before GH testing [1].

How Retesting Works Over Time

Adults diagnosed with childhood-onset GH deficiency require retesting during the transition period (typically ages 16 to 25) after achieving final height and completing at least one month off GH therapy. The 2011 Endocrine Society guideline recommends retesting unless the patient has three or more pituitary hormone deficits, a genetic cause, or structural hypothalamic-pituitary damage [1].

For adults diagnosed with GH deficiency in adulthood, retesting after treatment initiation is not routinely performed. The stimulation test confirmed the diagnosis. Ongoing treatment decisions rely on IGF-1 monitoring and clinical assessment.

There is one exception: if the original cause was potentially reversible (for example, post-traumatic brain injury within the first year, or after treatment of a functioning pituitary adenoma), retesting at 12 months can determine whether recovery occurred. A study by Tanriverdi et al. (2015, N=113 TBI patients) found that 21% of patients initially diagnosed with GH deficiency after traumatic brain injury recovered normal stimulated GH responses within 5 years [11].

Practical Steps Before Your Test

Preparation affects accuracy. Fasting for 8 to 12 hours before the test is standard for the ITT and GST. For macimorelin, an overnight fast of at least 8 hours is required per the prescribing information [4].

Patients should avoid vigorous exercise for 24 hours before testing, as exercise acutely raises GH and could mask a blunted response pattern. Hold oral estrogen for 4 to 6 weeks before testing if clinically feasible, since it lowers IGF-1 and may exaggerate the apparent deficit [1]. Blood glucose should be checked at baseline. For the ITT, the supervising physician must have IV dextrose and trained staff available for rescue from severe hypoglycemia.

Dr. Kevin Yuen of the Barrow Neurological Institute has emphasized that "proper test selection, BMI-appropriate cutoffs, and pre-test medication review are the three pillars of accurate GH stimulation testing" [2]. Skipping any of these steps introduces diagnostic error.

The test itself typically takes 2 to 4 hours depending on the stimulation agent. Results are usually available within 3 to 5 business days. A single confirmed low peak, or two low peaks in isolated suspected deficiency, sets the treatment conversation in motion.